Product Datasheet

Bfl-1-IN-6 TFA

Catalog No. **BP-02179A** · CAS **3106364-91-1** · Form **salt · salt** · Physical state **solid** · Version **1.0** · Revision **2026-09-04**

FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target	Research area
Bcl-2 Family; Caspase; Apoptosis	**Cancer**

Molecular formula	$C_{24}H_{25}ClF_4N_2O_4$
Molecular weight	**516.9130**

STRUCTURE



DESCRIPTION

Bfl-1-IN-6 TFA is a Covalent, Orally Bioavailable, and Selective BFL1 Inhibitor.

BIOLOGICAL ACTIVITY

In Vitro

Bfl-1-IN-6 (Compound 20) TFA induces caspase activation in SUDHL1 cells treated with 0.5 μM AZD5991 (HY-101533) with an EC50 of 350 nM, thereby resulting in decreased cell viability.

Bfl-1-IN-6 TFA combined with 0.5 μM AZD5991 reduces the viability of SUDHL1 cells, with an EC50 of 250 nM, and causes no significant off-target toxicity in BFL1-deficient Karpas-422 cells.

Bfl-1-IN-6 (0.3-9 μM; 6 h) TFA induces dose-dependent BFL1 stabilization and activation of cleaved caspase-3 in OCILY10 cells, and exhibits targeted apoptotic activity after 6 hours of treatment.

In Vivo

Bfl-1-IN-6 (Compound 20) (100-300 mg/kg; p.o.; single dose) TFA causes dose-dependent stabilization of BFL1 and activation of cleaved caspase 3 in OCILY10 lymphoma tumor xenografts in mice.

SOLUBILITY

soluble in DMSO

REFERENCES

[1]. Palisse A, et al. Structure-Based Discovery of a Series of Covalent, Orally Bioavailable, and Selective BFL1 Inhibitors. Journal of medicinal chemistry. 2024 Dec 26;67(24):22055-22079.